reports
- Jacob Mekhael
Inventiva FIRST LOOK: 2nd tranche of € 116m extends runway until end 3...
Inventiva announced that the Board of Directors called the 2nd tranche of its previously announced € 348m structured financing for gross proceeds of € 115.6m (net proceeds of € 108.5m), which comes in line expectations following the completion of recruitment in the phase 3 (NATiV3) trial of lanifibranor (pan-PPAR agonist) in MASH. We expect the 72 week treatment period to be completed in August 2026, and note that Inventiva is now funded until the end of 3Q26. We plan a model update to incorpora...
Inventiva secures the €116 million second tranche of its structured fi...
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases w...
Inventiva obtient la deuxième tranche de 116 millions d'euros de son f...
Inventiva obtient la deuxième tranche de 116 millions d'euros de son financement structuré d'un montant maximum de 348 millions d'euros Le financement intervient à la suite de la fin du recrutement de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor chez les patients atteints de MASH et à la suite de l’atteinte d’autres conditions préalables. Daix (France), New York City (New York, États-Unis), le 5 mai 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules adm...
Statement of total voting rights and shares forming the company’s shar...
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025 Article R. 22-10-23 of the French Commercial Code Market: Euronext ParisISIN code / Mnemo: FR0013233012 / IVAWeb site: DateNumber of shares outstandingTotal voting rights,gross (1)Total voting rights,net (2)April 11, 202595,662,391108,635,435108,574,827 The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to w...
Information relative au nombre total de droits de vote et d’actions co...
Information relative au nombre total de droits de vote et d’actions composant le capital social au 11 avril 2025 Article R. 22-10-23 du Code de commerce Place de cotation : Euronext ParisCode ISIN / Mnémo : FR0013233012 / IVASite web : Date Nombre de titres composant le capital en circulation Nombre total de droits de vote bruts(1) Nombre total de droits de vote nets(2) 11 avril 2025 95 662 391 108 635 435 108 574 827 Le nombre de droits de vote bruts (ou droits de vote « théoriques ») sert de base de calcul pour les franchissements de seuil. Conformément à l’articl...
Combined General Meeting of May 22, 2025 - Availability of the prepara...
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents Daix (France), New York City (New York, United States), April 30, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of Ma...
Assemblée Générale Mixte du 22 mai 2025 - Modalités de mise à disposit...
Assemblée Générale Mixte du 22 mai 2025 - Modalités de mise à disposition des documents préparatoires Daix (France), New York City (New York, Etats-Unis), le 30 avril 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH ») et d’autres maladies avec un besoin médical non satisfait, annonce aujourd’hui les modalités de mise à disposition des documents pré...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Lynn Hautekeete
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Inventiva Publishes results on predictive biomarker in MASH in journal
Inventiva announced publication in the peer-reviewed medical journal Clinical Gastroenterology and Hepatology, of its analysis on new non-invasive biomarker signatures predictive of histology response following treatment with lanifibranor (pan-PPAR agonist) in patients with MASH and fibrosis. While there are multiple diagnostic scores currently available, we are encouraged to learn that Inventiva's test suggested better predictive accuracy than existing options including FIB4. With recruitment i...
Inventiva announces the publication in Clinical Gastroenterology and H...
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor ► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis ► The biomarker signatures developed for fibrosis improvement, MASH resolution and composite histological endpoints, suggested better predictive accuracy than other diagnostic scores available including FIB4, FIBC3, ABC3D, NFS, ELF and MACK-3 ► ...
Inventiva annonce la publication dans Clinical Gastroenterology and He...
Inventiva annonce la publication dans Clinical Gastroenterology and Hepatology de l’analyse de nouvelles signatures de biomarqueurs prédictives de la réponse histologique chez les patients atteints de MASH traités par lanifibranor ► Des signatures de biomarqueurs ont été développées pour prédire la réponse histologique au traitement par lanifibranor chez les patients atteints de MASH avec fibrose ► Les signatures de biomarqueurs développées pour l’amélioration de la fibrose, la résolution de la MASH et les critères histologiques composites, ont suggéré une meilleure prédictivité que les ...
Inventiva announces filing of its 2024 Universal Registration Document...
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F Daix (France), New York City (New York, United States), April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that it had filed its 2024 Universal Registration Document for the year ended December ...
Inventiva annonce le dépôt de son Document d’Enregistrement Universel ...
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2024 et de son Rapport Annuel 2024 (« Form 20-F ») Daix (France), New York City (New York, États-Unis), le 15 avril 2025 - Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH ») et d'autres maladies avec un besoin médical non satisfait, annonce aujourd’hui avoir déposé son Document d’Enreg...
- Guy Sips
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Thomas Couvreur
- Wim Hoste
- Jacob Mekhael
Inventiva FIRST LOOK: Completes NATiV3 enrolment, topline results pinn...
Inventiva announced the completion of patient enrolment in its phase 3 (NATiV3) trial of lanifibranor (pan-PPAR agonist) in MASH. This is a key milestone, particularly in the context of the difficulties associated with MASH trial recruitment. As a result, the timeline for the topline readout is now pinned to 2H26 taking into account the 72 weeks treatment period. Subject to the second tranche of ~€ 116m from the financing announced in October 2024, which is expected to be triggered in 2Q25, Inve...
Inventiva announces completion of enrollment in the Phase 3 NATiV3 cli...
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from NATiV3 projected in the second half of 2026 and, if positive, expected to be the basis for submission for regulatory approval Daix (France), New York City (New York, United States), April 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical compan...
Inventiva annonce la fin du recrutement de l’étude clinique de Phase 3...
Inventiva annonce la fin du recrutement de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor chez les patients atteints de MASH et de fibrose avancée Objectifs de recrutement dépassés avec 1.009 patients randomisés dans la cohorte principale et 411 dans la cohorte exploratoirePrincipaux résultats de NATiV3 attendus au deuxième semestre 2026 et, si positifs, ils supporteront les demandes règlementaires d’autorisation de mise sur le marché Daix (France), New York City (New York, États-Unis), le 1 avril 2025 - Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Sociét...
- Jacob Mekhael
Inventiva FIRST LOOK: FY24 results confirm NATiV3 enrolment completion...
Inventiva reported FY24 results with a cash position of € 96.6m (YE23: €36m), providing a runway until mid 3Q25. The update comes in line with our expectations, and the progress made in recruitment for the phase 3 (NATiV3) trial of lanifibranor in MASH means the company continues to expect completion of enrolment in 1H25. This would secure the timeline for the topline readout, expected in 2H26. With the additional funding from the second tranche of the financing announced in October 2024 expecte...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Sharad Kumar S.P
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Inventiva reports its 2024 full year results and provides a business u...
Inventiva reports its 2024 full year results and provides a business update Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.